

The Iranian Society of Nuclear Medicine practical guideline on radioligand therapy in metastatic castration-resistant prostate cancer using ^{177}Lu -PSMA

Hojjat Ahmadzadehfar^{1,2}, Kamran Aryana³, Elahe Pirayesh², Saeed Farzanehfar⁴, Majid Assadi⁵, Babak Fallahi⁶, Babak Shafiei², Narjess Ayati³, Mahasti Amoui²

¹Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany

²Department of Nuclear Medicine, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

³Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

⁴Department of Nuclear Medicine, Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran

⁵The Persian Gulf Nuclear Medicine Research Center, The Persian Gulf Biomedical Research Institute, Bushehr University of Medical Sciences, Bushehr, Iran

⁶Research Centre for Nuclear Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran

(Received 16 July 2017, Revised 3 November 2017, Accepted 4 November 2017)

ABSTRACT

Prostate-specific membrane antigen (PSMA) is a type II transmembrane protein, which is anchored in the cell membrane of prostate epithelial cells. It is highly expressed on prostate epithelial cells and strongly up-regulated in prostate cancer. Although, ^{177}Lu -PSMA has been recently introduced for radionuclide therapy of metastatic castration-resistant prostate cancer (mCRPC) with continuously increasing interest and use worldwide. This guideline is intended to assist nuclear medicine physicians in evaluating and managing patients with mCRPC for whom radioligand therapy (RLT) using ^{177}Lu -PSMA is a promising treatment option. In addition, more information could be provided by subsequent investigative studies in the field of RLT.

Key words: Prostatic neoplasms; Neoplasm metastasis; Radionuclide therapy; ^{177}Lu -PSMA; Radioligand therapy

Iran J Nucl Med 2018;26(1):2-8

Published: January, 2018

<http://irjnm.tums.ac.ir>

Corresponding author: Dr. Mahasti Amoui, Department of Nuclear Medicine, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. E-mail: amoui@sbmu.ac.ir

PURPOSE

The purpose of this guideline is to assist nuclear medicine physicians in evaluating, treating and managing patients who eligible for radioligand therapy (RLT) are using ^{177}Lu -PSMA ligands in metastatic castration-resistant prostate cancer (mCRPC).

BACKGROUND INFORMATION AND DEFINITIONS

Definitions

CRPC: CRPC is defined as castrate serum testosterone <50 ng/dl or 1.7 nmol/l plus one of the following types of progression [1]:

- *Biochemical progression:* Three consecutive rises in PSA 1 week apart, resulting in two 50% increases over the nadir, and PSA >2 ng/ml.
- *Radiologic progression:* The appearance of new lesions; either two or more new bone lesions on bone scan or a soft tissue lesion using the Response Evaluation Criteria in Solid Tumors.

PSMA: Prostate-specific membrane antigen (PSMA), also known as folate hydrolase I or glutamate carboxypeptidase II, is a type II transmembrane protein, which is anchored in the cell membrane of prostate epithelial cells. PSMA is highly expressed on prostate epithelial cells and strongly up-regulated in prostate cancer. The PSMA expression levels are directly correlated to androgen independence, metastasis, and prostate cancer progression [2]. Thus, PSMA is a promising molecular target for diagnosis and therapy of metastatic prostate cancer at present [3].

Lutetium-177 (^{177}Lu): ^{177}Lu is a β - and γ -emitting radionuclide with a physical half-life of 6.7 days. It has a maximum and mean β -particle energy of 0.498 MeV and 0.133 MeV, respectively. The maximum and mean soft-tissue penetration depth of ^{177}Lu is 1.7 mm and 0.23 mm, respectively. It has two main gamma emission lines: 113 keV (6% relative abundance) and 208 keV (11% relative abundance).

^{177}Lu -PSMA-617: ^{177}Lu -PSMA-617, a DOTA derivative of the Glu-urea-Lys motif, has been developed in the German Cancer Research Center (DKFZ) Heidelberg, Germany, for the treatment of patients with metastatic prostate cancer [4, 5].

RLT: Radioligand therapy in this context involves the systemic intravenous administration of a specific well-defined radiopharmaceutical composed of a β -emitting radionuclide chelated to a peptide for the purpose of delivering cytotoxic radiation to cancer cells.

Background

Most deaths related to prostate cancer are due to advanced disease, which results from any combination of lymphatic, blood, or contiguous local spread. Targeted radionuclide therapy is an attractive and quickly developing therapy option for many different cancers, such as lymphoma, melanoma, and neuroendocrine tumours [6-9]. After the rather unsuccessful therapy with 90Y-CYT-356 monoclonal antibody (mAb), which binds to the intracellular domain of PSMA [10], Phase 1 and 2 clinical trials utilising the PSMA mAb J591, radiolabelled with ^{177}Lu or 90Y, have shown promising results [11-14]; however, there were higher rates of haematological toxicity. Tagawa et al. [11] treated 47 patients with ^{177}Lu -PSMA mAb J591. They reported grade 4 thrombocytopenia in 46.8% (29.8% received platelet transfusions) and a total of 25.5% experienced grade 4 neutropenia. Monoclonal antibodies are large molecules and therefore show poor permeability in solid tumours. This characteristic along with slow clearance from the circulation is probably the cause of grade 4 haematotoxicity. Maresca et al. described the design and synthesis of a series of small molecule inhibitors of PSMA, instead of mAb [15]. First clinical experiences with PSMA-based radionuclide treatment using Iodine-131-labelled PSMA showed promising results with mild haematotoxicity and a PSA decrease $>50\%$ in 60% of all treated prostate cancer patients [16]. ^{131}I has a long half-life of 8.02 days and a maximum beta-particle range in soft tissue of 2.4 mm. Due to the gamma-emitting properties and long half-life, ^{131}I is less attractive from a radiation safety point of view. In contrast, ^{177}Lu has a half-life of 6.7 days and a lower beta-particle emission energy, meaning that there is a high probability of fewer side effects [17, 18].

In the first patient cohort of ten patients, the study groups of University Hospitals Bonn and Muenster in Germany reported a low side effects profile and also good response according to PSA changes in the mCRPC patients after one cycle of RLT with ^{177}Lu -PSMA-617 [19]. A PSA decline was reported in 70% of the patients, and more than 50% decline in 5 patients. The results of this preliminary study were confirmed by two multicentre retrospective studies, which showed a low haematotoxicity and nephrotoxicity profile of this therapy with a PSA decline more than 50% in up to 45% of patients [20, 21]. Ferdinandus et al. evaluated the predictive value of different pre-therapeutic parameters on therapy response, considering changes in PSA after the first cycle of RLT [22]. In this study, the multivariate analysis showed that patients with a high platelet count or a regular need for analgesics had a significantly worse response after the first RLT cycle, considering any PSA decline after 2 months.

When a PSA decline > 50% was considered, patients with a regular need for analgesics showed a worse response, however, other pre-therapeutic parameters including prior therapies and the amount of PSMA uptake in ⁶⁸Ga-PSMA PET imaging, measured by SUV max, had no impact on patient response [22]. Rahbar et al. showed in a multicenter analysis of 145 patients that the presence of visceral metastases and an alkaline phosphatase ≥ 220 U/L were negative predictors of therapy response [20]. The study group of Bonn evaluated the haematotoxicity and nephrotoxicity in patients who received at least three cycles of RLT [23, 24]. They studied 49 patients who were treated with three cycles of ¹⁷⁷Lu-PSMA-617 and reported anaemia, thrombocytopenia and leukopenia (common toxicity criteria; CTC 3°) during the observation period after the third cycle in only 4 (8.2%), 3 (6.1%) and 0 patients, respectively. No CTC 4° haematotoxicity was observed in the entire study population. More than 60% of patients did not show any haematotoxicity [24]. In this study, 20 patients (40.8%) received a median of 6 cycles of radionuclide therapy with ²²³Ra prior to ¹⁷⁷Lu-PSMA-617 therapy. There were no significant differences between the patients with a history of therapy with ²²³Ra and those without regarding leukopenia and thrombocytopenia. These results confirmed that performing repeated cycles of ¹⁷⁷Lu-PSMA-617 after radionuclide therapy using ²²³Ra seems to be safe with a very small probability of haematotoxicity [24]. Yordanova et al. studied 55 patients who received at least 3 cycles of RLT with ¹⁷⁷Lu-PSMA-617 and showed no grade 3 or 4 nephrotoxicity [23]. A significant negative effect on renal function was found for age (>65 y) ($p = 0.049$), hypertension ($p = 0.001$) and pre-existing kidney disease ($p = 0.001$). Rahbar et al. reported the overall survival benefit of RLT in comparison to a historical collective. They demonstrated that the estimated median survival was 29.4 weeks, which was significantly longer than the survival in the historical control group with 19.7 weeks (Hazard Ratio: 0.44 (95% confidence interval: 0.20-0.95); $P = 0.031$) [25]. According to Ahmadzadehfar et al. [26] it seems that patients with a favourable response and repeated therapies with ¹⁷⁷Lu-PSMA-617 have a significantly longer overall-survival in comparison to patients who showed no response to RLT according to PSA changes. According to Braeuer et al. an initial ALP level <220 U/L and a PSA decline measured two months after the first cycle were associated with a longer OS [27]. Delker et al. reported their dosimetry results with ¹⁷⁷Lu-PSMA-617 and calculated a mean absorbed dose/per cycle to the bone marrow, kidneys, liver, spleen and salivary glands of 0.012 Gy/GBq, 0.6 Gy/GBq, 0.1 Gy/GBq, 0.1 Gy/GBq and 1.4 Gy/GBq, respectively [28].

Regarding the different promising results, ¹⁷⁷Lu-PSMA-617 is a new and promising therapy option for

patients with mCRPC but has not yet reached clinical approval. It should therefore mostly be offered to patients as a salvage therapy.

The aim of this guideline is to provide a scientific and ethical platform for this useful treatment to initially pursue its application, preferably in academic centers in Iran under controlled investigational protocols.

REGULATORY ISSUES

RLT with ¹⁷⁷Lu-PSMA-617 -like other radionuclide therapies with an unsealed source- must be performed only by experienced Nuclear Medicine specialists. At the moment, in Iran, this therapy should only be undertaken by Nuclear Medicine specialists enrolled in an investigational protocol pursuant to a valid investigational radiopharmaceutical under the purview of a qualified institutional review board.

INDICATIONS AND CONTRAINDICATIONS

Indications

RLT with ¹⁷⁷Lu-PSMA-617 is indicated for the treatment of patients with mCRPC, who do not have any other approved therapy option planned by a multidisciplinary team. Candidate patients for RLT using ¹⁷⁷Lu-PSMA-617 should fulfil the following criteria:

- mCRPC with PSMA positive metastatic disease upon PSMA-PET or SPECT imaging.
 - There is no limitation regarding the number or site of metastases, i.e. bone or soft tissue metastases. Caution should be given to patients with diffuse bone marrow and brain metastasis.
- after initial hormone therapy (LH-RH agonists/antagonists) and
 - Progressive disease despite newly developed hormone therapies (Abiraterone/Enzalutamide) or these medications avoided by the patient.
 - Progressive disease despite chemotherapy (Docetaxel and Cabecitaxel) or the patient being unfit for chemotherapy or avoiding chemotherapy.
- Not suitable for ¹⁵³Sm-EDTMP or ²²³Ra-dichloride or other local available radiopharmaceuticals for bone-targeted therapies due to extra-osseous metastases or diffuse bone marrow metastases or avoided by the patient.
 - In patients without adequate response to bone-targeted therapies for pain palliation or exacerbation of pain even by such

therapy, an RLT with ¹⁷⁷Lu-PSMA-617 can be evaluated [24].

- Life expectancy longer than 4-6 months.
- Decision for salvage therapy at the institutional interdisciplinary tumour board.

In summary, mCRPC patients should undergo hormone therapy and chemotherapy as well as bone targeted therapy, if indicated. In the case of any contraindication for one of these therapies, it should be discussed and documented in an interdisciplinary tumour board.

Contraindications

- WBC $\leq 2 \times 10^3/\mu\text{l}$.
- Hb ≤ 8 g/dl.
 - In the case of symptomatic anaemia, a red-blood-cell transfusion should precede the therapy. RLT with ¹⁷⁷Lu-PSMA-617 may have a positive effect on bone marrow depression, causing the need for less blood to be transfused due to tumour regression in bone marrow [29]. It should be mentioned that pure anaemia without thrombocytopenia and leucopenia is not a contraindication for RLT.
- Platelets $\leq 75 \times 10^3/\mu\text{l}$.
- Creatinine > 2 mg/dl.
- Renal outflow obstruction.
- Previous chemotherapy or bone-targeted radionuclide therapy and extended external beam irradiation fields to the bone marrow (pelvis, spine), if performed during 4 weeks preceding the RLT.
- ECOG > 2 .

PREPARATION PRIOR TO RLT

- Prostate cancer proven by histopathology.
- Any PSMA-PET or SPECT imaging (as labelled with ⁶⁸Ga or ^{99m}Tc) to verify PSMA positive lesions.
 - In the case of liver or brain metastases, diagnostic imaging with CT or MRI should be performed to rule-out any PSMA negative metastases. If PSMA-negative liver or brain metastases exist, a multidisciplinary team should evaluate a combination therapy with other modalities (external beam radiation or local interventional therapies).
- Renal scintigraphy to evaluate renal function and rule out obstructive dysfunctions.
 - In the case of obstructive dysfunction, it should be treated first.

- The renal scintigraphy should be performed prior to the first cycle. Performing further renal scintigraphies prior to the next cycles is optional and depends on the renal function tests and the results of the first renal scintigraphy.

- Complete blood counts, renal function tests (creatinine and GFR), liver function tests, ALP, LDH, CRP and PSA should be examined prior to each cycle.

ADMINISTRATION

- Cooling the salivary glands, the patients receive ice packs over the parotid and submandibular glands from 30 min prior to and up to 4 hours after administration of ¹⁷⁷Lu-PSMA-617 to reduce the risk of salivary gland radiation injuries.
 - There is no evidence of whether cooling the salivary glands is an effective therapy for saving these glands from radiation; however, it is tolerable and not harmful for the patients.
- Using a urinary catheter in incontinent patients in the first 48 hours to avoid any contamination.
- Activity of 6 GBq (range: 5.5-6.5 GBq) ¹⁷⁷Lu-PSMA-617.
 - The amount of activity can be reduced to 4.0-5.0 GBq in the case of impaired renal function (e.g. Creatinine 1.5-2).
 - According to the preliminary results, an activity of 7.4 GBq can be administered safely; however, more data are required to increase the amount of activity.
- Injection of the activity intravenously as a slow bolus (over about 30 seconds) followed by 1000 ml Ringer or NaCl.
 - The patients should be encouraged to void as frequently as possible and drink about 2 litres of water daily.
 - In patients with dilated non-obstructive renal disease an administration of 40 mg Furosemide may be meaningful.
- 4 cycles of the RLT every 6-8 weeks.
 - In the case of continuously increasing PSA, after the first two cycles accompanied by worsening of the general condition, the indication of further RLTs should be re-evaluated.
 - In case of a decreasing PSA to < 1.0 ng/ml during the therapy cycles, a PSMA imaging could evaluate existence of small PSMA-positive metastases after

completion of RLT when post injection SPECT study is not enough informative.

- In case of a significant decline of platelets or leucocytes, the time interval between the 2 cycles can be prolonged.
- At least one whole body scan 24-48 hours post injection (preferably with SPECT(/CT)).

In patients with diffuse bone and bone marrow metastases as well as in patients with brain metastases a concomitant corticosteroid therapy (e.g. prednisolone 20 mg/daily) in the first two weeks after administration is advisable.

SIDE EFFECTS

Acute

According to the results of different published data, no severe adverse events immediately after injection have been reported to date [19, 25, 30-35]. The most common side effect in the first 48 hours after injection is mild nausea & vomiting (in up to 20% of patients) [20, 30, 31], which can be easily treated with Ondansetron. Fatigue is the most common complaint in patients after therapy, especially in the first 4 weeks (in up to 25%) [20, 30, 31].

Delayed side effects

Dry mouth was reported in up to 20% of cases and is transient and tolerable in the majority of patients [19, 25, 30, 36].

Renal toxicity

Dosimetry studies have shown that the most critical organs are the kidneys, with a maximum kidney radiation dose of 0.88 Gy/GBq for ¹⁷⁷Lu-PSMA-617 and 0.93 Gy/GBq for ¹⁷⁷Lu-PSMA-I&T [37, 38]. None of the current studies have reported any high grade nephrotoxicity (CTC grade 3, 4 or 5) [19, 20, 25, 30, 36, 39]. In a recently published study by Yordanova et al., the authors reported renal toxicity in 55 mCRPC patients who received at least 3 cycles of ¹⁷⁷Lu-PSMA-617. They observed increased creatinine levels of CTC 1° or 2° in 14 patients (25%) and increased GFR (grade 1/2) in 16 cases. None of the 55 patients experienced severe nephrotoxicity (grade 3/4) [23].

Bone marrow toxicity

Severe (grade 3 and 4) bone marrow toxicity is observed in less than 10% of patients in various publications [24, 40].

FOLLOW-UP

- PSMA-PET or SPECT imaging before the first and after the fourth cycle in the case of

continuously increasing PSA or PSA-decline to <1.0 ng/ml (as mentioned above), a PSMA-imaging is recommended for re-evaluating of further cycles).

- CBC and renal function test every 2-3 weeks; PSA could be monitored every 4 weeks.

THERAPY OF RECURRENT DISEASE

- If an increase in the level of PSA is documented after a good response following the first course of treatment (3 to 4 cycles of RLT), another course of therapy can be performed. For a second treatment course:

- The patient should be evaluated in a tumor board again.
- PSMA imaging is mandatory for documentation of PSMA positive metastases
- The aforementioned exclusion criteria should be considered.

FACILITY AND PERSONNEL

RLT with ¹⁷⁷Lu-PSMA-617 is still considered an investigational treatment and its implementation must comply with Iranian legislation and requirements, as well as with ethical principles regarding human studies. The decision to perform RLT should be taken by a multidisciplinary team, including all of the specialists involved in the care of patients with mCRPC. The treatment should take place in an approved nuclear medicine department and must be performed by an experienced Nuclear Medicine specialist. The Nuclear Medicine ward must have qualified personnel, appropriate radiation safety equipment and procedures for waste management and handling accidental contamination of the site or personnel. Isolation of patients in nuclear medicine department should be performed according to local radiation regulations for patient release after radionuclide therapy.

REFERENCES

1. Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, van der Poel HG, van der Kwast TH, Rouvière O, Wiegel T, Mottet N. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. *Eur Urol*. 2017 Apr;71(4):630-642.
2. Santoni M, Scarpelli M, Mazzucchelli R, Lopez-Beltran A, Cheng L, Cascinu S, Montironi R. Targeting prostate-specific membrane antigen for personalized therapies in prostate cancer: morphologic and molecular backgrounds and future promises. *J Biol Regul Homeost Agents*. 2014 Oct-Dec;28(4):555-63.

3. Haberkorn U, Eder M, Kopka K, Babich JW, Eisenhut M. New Strategies in Prostate Cancer: Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and Therapy. *Clin Cancer Res.* 2016 Jan 1;22(1):9-15.
4. Hillier SM, Maresca KP, Femia FJ, Marquis JC, Foss CA, Nguyen N, Zimmerman CN, Barrett JA, Eckelman WC, Pomper MG, Joyal JL, Babich JW. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. *Cancer Res.* 2009 Sep 1;69(17):6932-40.
5. Kratochwil C, Giesel FL, Eder M, Afshar-Oromieh A, Benešová M, Mier W, Kopka K, Haberkorn U. [¹⁷⁷Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. *Eur J Nucl Med Mol Imaging.* 2015 May;42(6):987-8.
6. Kraeber-Bodéré F, Bodet-Milin C, Rousseau C, Eugène T, Pallardy A, Frampas E, Carlier T, Ferrer L, Gaschet J, Davodeau F, Gustin JF, Faivre-Chauvet A, Barbet J, Chérel M. Radioimmunoconjugates for the treatment of cancer. *Semin Oncol.* 2014 Oct;41(5):613-22.
7. Mier W, Kratochwil C, Hassel JC, Giesel FL, Beijer B, Babich JW, Friebe M, Eisenhut M, Enk A, Haberkorn U. Radiopharmaceutical therapy of patients with metastasized melanoma with the melanin-binding benzamide 131I-BA52. *J Nucl Med.* 2014 Jan;55(1):9-14.
8. van der Zwan WA, Bodei L, Mueller-Brand J, de Herder WW, Kvols LK, Kwekkeboom DJ. GEPNETs update: Radionuclide therapy in neuroendocrine tumors. *Eur J Endocrinol.* 2015 Jan;172(1):R1-8.
9. Bodei L, Kidd M, Paganelli G, Grana CM, Drozdov I, Cremonesi M, Lepensky C, Kwekkeboom DJ, Baum RP, Krenning EP, Modlin IM. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. *Eur J Nucl Med Mol Imaging.* 2015 Jan;42(1):5-19.
10. Deb N, Goris M, Trisler K, Fowler S, Saal J, Ning S, Becker M, Marquez C, Knox S. Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody. *Clin Cancer Res.* 1996 Aug;2(8):1289-97.
11. Tagawa ST, Milowsky MI, Morris M, Vallabhajosula S, Christos P, Akhtar NH, Osborne J, Goldsmith SJ, Larson S, Taskar NP, Scher HI, Bander NH, Nanus DM. Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. *Clin Cancer Res.* 2013 Sep 15;19(18):5182-91.
12. Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ. Phase I trial of ¹⁷⁷lutetium-labeled J591, a monoclonal antibody for prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. *J Clin Oncol.* 2005 Jul 20;23(21):4591-601.
13. Vallabhajosula S, Goldsmith SJ, Hamacher KA, Kostakoglu L, Konishi S, Milowski MI, Nanus DM, Bander NH. Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and ¹⁷⁷Lu-labeled J591 antibodies specific for prostate-specific membrane antigen. *J Nucl Med.* 2005 May;46(5):850-8.
14. Vallabhajosula S, Goldsmith SJ, Kostakoglu L, Milowsky MI, Nanus DM, Bander NH. Radioimmunotherapy of prostate cancer using 90Y- and ¹⁷⁷Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity. *Clin Cancer Res.* 2005 Oct 1;11(19 Pt 2):7195s-7200s.
15. Maresca KP, Hillier SM, Femia FJ, Keith D, Barone C, Joyal JL, Zimmerman CN, Kozikowski AP, Barrett JA, Eckelman WC, Babich JW. A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer. *J Med Chem.* 2009 Jan 22;52(2):347-57.
16. Zechmann CM, Afshar-Oromieh A, Armor T, Stubbs JB, Mier W, Hadaschik B, Joyal J, Kopka K, Debus J, Babich JW, Haberkorn U. Radiation dosimetry and first therapy results with a (¹²⁴I)/ (¹³¹I)-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. *Eur J Nucl Med Mol Imaging.* 2014 Jul;41(7):1280-92.
17. Kam BL, Teunissen JJ, Krenning EP, de Herder WW, Khan S, van Vliet EI, Kwekkeboom DJ. Lutetium-labelled peptides for therapy of neuroendocrine tumours. *Eur J Nucl Med Mol Imaging.* 2012 Feb;39 Suppl 1:S103-12.
18. Afshar-Oromieh A, Haberkorn U, Zechmann C, Armor T, Mier W, Spohn F, Debus N, Holland-Letz T, Babich J, Kratochwil C. Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with ¹³¹I-MIP-1095. *Eur J Nucl Med Mol Imaging.* 2017 Jun;44(6):950-959.
19. Ahmadzadehfar H, Rahbar K, Kürpig S, Bögemann M, Claesener M, Eppard E, Gärtner F, Rogenhof S, Schäfers M, Essler M. Early side effects and first results of radioligand therapy with (¹⁷⁷Lu)-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. *EJNMMI Res.* 2015 Dec;5(1):114.
20. Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schäfers M, Essler M, Baum RP, Kulkarni HR, Schmidt M, Drzezga A, Bartenstein P, Pfestroff A, Luster M, Lützen U, Marx M, Prasad V, Brenner W, Heinzel A, Mottaghy FM, Ruf J, Meyer PT, Heuschkel M, Eveslage M, Bögemann M, Fendler WP, Krause BJ. German multicenter study investigating ¹⁷⁷Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. *J Nucl Med.* 2017 Jan;58(1):85-90.
21. Rahbar K, Schmidt M, Heinzel A, Eppard E, Bode A, Yordanova A, Claesener M, Ahmadzadehfar H. Response and tolerability of a single dose of ¹⁷⁷Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: A multicenter retrospective analysis. *J Nucl Med.* 2016 Sep;57(9):1334-8.
22. Ferdinandus J, Eppard E, Gaertner FC, Kürpig S, Fimmers R, Yordanova A, Hauser S, Feldmann G, Essler M, Ahmadzadehfar H. Predictors of response to radioligand therapy of metastatic castrate-resistant prostate cancer with ¹⁷⁷Lu-PSMA-617. *J Nucl Med.* 2017 Feb;58(2):312-319.
23. Yordanova A, Becker A, Eppard E, Kürpig S, Fisang C, Feldmann G, Essler M, Ahmadzadehfar H. The impact of repeated cycles of radioligand therapy using [¹⁷⁷Lu]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer. *Eur J Nucl Med Mol Imaging.* 2017 Aug;44(9):1473-1479.
24. Ahmadzadehfar H, Zimbelmann S, Yordanova A, Fimmers R, Kürpig S, Eppard E, Gaertner FC, Wei X, Hauser S, Essler M. Radioligand therapy of metastatic prostate cancer using ¹⁷⁷Lu-PSMA-617 after radiation exposure to ²²³Ra-dichloride. *Oncotarget.* 2017 Feb 25;8(33):55567-55574.
25. Rahbar K, Bode A, Weckesser M, Avramovic N, Claesener M, Stegger L, Bögemann M. Radioligand Therapy With ¹⁷⁷Lu-PSMA-617 as a novel therapeutic option in patients with metastatic castration resistant prostate cancer. *Clin Nucl Med.* 2016 Jul;41(7):522-8.
26. Ahmadzadehfar H, Wegen S, Yordanova A, Fimmers R, Kürpig S, Eppard E, Wei X, Schlenkhoff C, Hauser S, Essler M. Overall survival and response pattern of

- castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [¹⁷⁷Lu]Lu-PSMA-617. *Eur J Nucl Med Mol Imaging*. 2017 Aug;44(9):1448-1454.
27. Bräuer A, Grubert LS, Roll W, Schrader AJ, Schäfers M, Bögemann M, Rahbar K. ¹⁷⁷Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer. *Eur J Nucl Med Mol Imaging*. 2017 Sep;44(10):1663-1670.
 28. Delker A, Fendler WP, Kratochwil C, Brunegrab A, Gosewisch A, Gildehaus FJ, Tritschler S, Stief CG, Kopka K, Haberkorn U, Bartenstein P, Böning G. Dosimetry for (¹⁷⁷Lu)-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. *Eur J Nucl Med Mol Imaging*. 2016 Jan;43(1):42-51. d
 29. Schlenkhoff CD, Gaertner F, Essler M, Schmidt M, Ahmadzadehfar H. Positive Influence of ¹⁷⁷Lu PSMA-617 Therapy on Bone Marrow Depression Caused by Metastatic Prostate Cancer. *Clin Nucl Med*. 2016 Jun;41(6):478-80.
 30. Ahmadzadehfar H, Eppard E, Kürpig S, Fimmers R, Yordanova A, Schlenkhoff CD, Gärtner F, Rogenhofer S, Essler M. Therapeutic response and side effects of repeated radioligand therapy with ¹⁷⁷Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer. *Oncotarget*. 2016 Mar 15;7(11):12477-88.
 31. Braat AJAT, Ahmadzadehfar H. Lutetium-177 labelled PSMA ligands for the treatment of metastatic castrate-resistant prostate cancer. *Tijdschr Nucl Geneesk*. 2016;38(4):1627-1634.
 32. Fendler WP, Kratochwil C, Ahmadzadehfar H, Rahbar K, Baum RP, Schmidt M, Pfestroff A, Lützen U, Prasad V, Heinzel A, Heuschkel M, Ruf J, Bartenstein P, Krause BJ. ¹⁷⁷Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer. *Nuklearmedizin*. 2016 Jun 28;55(3):123-8.
 33. Budäus L, Leyh-Bannurah SR, Salomon G, Michl U, Heinzer H, Huland H, Graefen M, Steuber T, Rosenbaum C. Initial experience of (⁶⁸Ga)-PSMA PET/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy. *Eur Urol*. 2016 Mar;69(3):393-6.
 34. Kulkarni HR, Singh A, Schuchardt C, Niepsch K, Sayeg M, Leshch Y, Wester HJ, Baum RP. PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013. *J Nucl Med*. 2016 Oct;57(Suppl 3):97S-104S.
 35. Kratochwil C, Giesel FL, Stefanova M, Benešová M, Bronzel M, Afshar-Oromieh A, Mier W, Eder M, Kopka K, Haberkorn U. PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with ¹⁷⁷Lu-Labeled PSMA-617. *J Nucl Med*. 2016 Aug;57(8):1170-6.
 36. Baum RP, Kulkarni HR, Schuchardt C, Singh A, Wirtz M, Wiessalla S, Schottelius M, Mueller D, Klette I, Wester HJ. ¹⁷⁷Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy. *J Nucl Med*. 2016 Jul;57(7):1006-13.
 37. Okamoto S, Thieme A, Allmann J, D'Alessandria C, Maurer T, Retz M, Tauber R, Heck MM, Wester HJ, Tamaki N, Fendler WP, Herrmann K, Pfob CH, Scheidhauer K, Schwaiger M, Ziegler S, Eiber M. Radiation dosimetry for ¹⁷⁷Lu-PSMA I&T in metastatic castration-resistant prostate cancer: Absorbed dose in normal organs and tumor lesions. *J Nucl Med*. 2017 Mar;58(3):445-450.
 38. Kabasakal L, AbuQbeith M, Aygün A, Yeyin N, Ocak M, Demirci E, Toklu T. Pre-therapeutic dosimetry of normal organs and tissues of (¹⁷⁷Lu)-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer. *Eur J Nucl Med Mol Imaging*. 2015 Dec;42(13):1976-83.
 39. Yordanova A, Becker A, Eppard E, Kürpig S, Fisang C, Feldmann G, Essler M, Ahmadzadehfar H. The impact of repeated cycles of radioligand therapy using [¹⁷⁷Lu]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer. *Eur J Nucl Med Mol Imaging*. 2017 Aug;44(9):1473-1479.
 40. Emmett L, Willowson K, Violet J, Shin J, Blanksby A, Lee J. Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy. *J Med Radiat Sci*. 2017 Mar;64(1):52-60.